Edesa Biotech (EDSA) AI Stock Analysis

• Market Cap: $61.36M
• Dividend Yield: N/A
• Average Volume (3M): 93.40K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.89
• Revenue Growth: N/A
• EPS Growth: 30.29%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.28
• Shares Outstanding: 8,348,161
• 10 Day Avg. Volume: 65,583
• 30 Day Avg. Volume: 93,401
• PEG Ratio: 0.06
• Price to Book (P/B): 1.13
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.91
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -535.31
• Enterprise Value/Ebitda: -7.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -1.62
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $7.50 ▲(406.76% Upside)
• Action: Reiterated Date: 03/08/26
• Date: Action: Reiterated 03/08/26

The score is held back primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn). Technicals are strong with price well above moving averages and positive MACD, but elevated RSI suggests the move may be overextended. A positive catalyst is the reported Phase 3 clinical data, which supports the pipeline outlook, while valuation remains constrained by negative earnings and no dividend.

Positive Factors

Positive Phase 3 paridiprubart results

Statistically significant mortality reduction across the full study population materially de-risks the lead program. Durable clinical efficacy across severities supports regulatory filings, label strength and payer negotiation, improving long-term commercial and partnership prospects.

IP filings and government-funded trials

Provisional patents extend intellectual property protection prospects while government-funded trials and manufacturing scale-up signal external validation and non-dilutive support. Together they reduce execution risk and enhance attractiveness to partners and acquirers.

Conservative leverage and stronger equity base

Minimal debt lowers financial risk and interest burden, while a meaningful increase in equity improves capitalization. This balance-sheet strength provides a longer runway to advance late-stage development and negotiate licensing without heavy debt constraints.

Negative Factors

No revenue; sustained losses

The absence of commercial revenue means the company remains a development-stage operation dependent on clinical progress. Continued net losses limit internal reinvestment capacity, increase the probability of dilution, and imply a multi-period path before profitable operations if trials or approvals are delayed.

Persistent negative operating and free cash flow

Ongoing cash burn constrains the firm’s ability to self-fund development and commercialization. Even with improvement versus earlier years, negative FCF reduces strategic flexibility, increases reliance on external financing, and raises dilution and execution risk over the medium term.

Continued reliance on external capital; negative returns

Dependence on outside funding is a structural vulnerability: financing availability and terms will shape development pacing. Deeply negative ROE signals capital is not generating returns, weakening bargaining power with partners and increasing the chance of unfavorable dilution if markets tighten.

Edesa Biotech Business Overview & Revenue Model

Company Description

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

How the Company Makes Money

null

Edesa Biotech Financial Statement Overview

Summary

Development-stage profile: no revenue and sizable TTM losses (net income and EBITDA about -$7.8M) with negative operating/free cash flow (about -$7.9M). Positives include minimal leverage (debt-to-equity near 0) and a stronger equity base versus FY2024, but returns remain deeply negative and the business still relies on external capital.

Income Statement

TTM (Trailing-Twelve-Months) shows no revenue and continued heavy losses (net income about -$7.8M; EBITDA about -$7.8M). While losses are narrower versus FY2022 (net loss about -$17.5M) and improved from FY2023, the business still lacks commercial scale and remains structurally unprofitable, which keeps the income statement profile weak.

Balance Sheet

The balance sheet is conservatively levered, with essentially no debt in recent periods (debt-to-equity near 0), which reduces financial risk. Equity has risen meaningfully versus FY2024 (about $14.0M TTM vs. ~$2.0M FY2024), improving the capitalization base; however, returns remain deeply negative (TTM return on equity around -65%), reflecting ongoing losses and continued reliance on funding to sustain operations.

Cash Flow

Cash generation is a key pressure point: TTM operating cash flow is about -$7.9M and free cash flow about -$7.9M, indicating ongoing cash burn to fund operations. Cash burn improved versus FY2022 (free cash flow about -$12.3M), but free cash flow remains consistently negative and closely tracks net losses, leaving limited internal funding capacity.

Breakdown	TTM	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-101.62K	-119.27K	-186.05K	-183.47K	-118.19K	-118.79K
EBITDA	-7.77M	-7.07M	-5.98M	-8.19M	-17.43M	-13.22M
Net Income	-7.82M	-7.19M	-6.17M	―	-17.55M	-13.34M
Balance Sheet
Total Assets	14.71M	13.53M	3.81M	8.89M	11.58M	14.58M
Cash, Cash Equivalents and Short-Term Investments	12.05M	10.79M	1.04M	5.36M	7.09M	7.84M
Total Debt	0.00	0.00	19.87K	94.49K	18.98K	99.32K
Total Liabilities	756.16K	1.08M	1.83M	1.84M	2.18M	1.53M
Stockholders Equity	13.95M	12.45M	1.98M	7.05M	9.39M	13.06M
Cash Flow
Free Cash Flow	-7.94M	-7.32M	-4.89M	-6.64M	-12.28M	-13.67M
Operating Cash Flow	-7.94M	-7.32M	-4.89M	-6.64M	-12.28M	-13.66M
Investing Cash Flow	0.00	0.00	0.00	0.00	-5.66K	-6.15K
Financing Cash Flow	18.59M	17.03M	592.03K	4.83M	11.63M	14.17M

Edesa Biotech Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.48
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EDSA, the sentiment is Positive. The current price of 1.48 is below the 20-day moving average (MA) of 4.47, below the 50-day MA of 2.55, and below the 200-day MA of 2.21, indicating a bullish trend. The MACD of 1.47 indicates Negative momentum. The RSI at 69.14 is Neutral, neither overbought nor oversold. The STOCH value of 69.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EDSA.

Edesa Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EDSA	52 Neutral	$61.36M	-1.26	-55.75%	―	―	30.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LPCN	45 Neutral	$52.19M	-4.54	-59.29%	―	-44.31%	-34.17%
COCP	45 Neutral	$14.20M	-1.68	-94.94%	―	―	49.10%
XTLB	39 Underperform	$6.39M	-5.27	―	―	―	65.45%
BIVI	38 Underperform	$9.05M	-0.38	-94.79%	―	―	84.44%

Edesa Biotech Corporate Events

Edesa Biotech Reports Positive Phase 3 Paridiprubart Results

On February 24, 2026, Edesa Biotech reported additional positive Phase 3 data for paridiprubart from a 278-patient study, showing a statistically significant reduction in adjusted 28-day mortality to 24% from 33% versus placebo across the full treatment population. Benefits were consistent across severity levels and comorbidities, with higher clinical improvement rates by Day 28 and a safety profile comparable to placebo, reinforcing the drug’s potential in critical care settings.

Exploratory analyses showed that in 174 non-ventilated patients, paridiprubart plus standard of care cut adjusted 28-day mortality to 15% from 23%, and mortality reductions of 30%-36% were observed in patients with pneumonia, acute kidney injury and sepsis. Building on these results, Edesa has filed provisional patents for using paridiprubart in these indications, while parallel government-funded trials and manufacturing scale-up support the company’s late-stage development and commercial-readiness strategy.

The most recent analyst rating on (EDSA) stock is a Sell with a $0.73 price target. To see the full list of analyst forecasts on Edesa Biotech stock, see the EDSA Stock Forecast page.